key: cord-0832836-0d2j9zj7 authors: Niaki, Omid Zahedi; Anadkat, Milan J.; Chen, Steven T.; Fox, Lindy P.; Harp, Joanna; Micheletti, Robert G.; Nambudiri, Vinod E.; Pasieka, Helena B.; Shinohara, Michi M.; Rosenbach, Misha; Merola, Joseph F. title: Navigating Immunosuppression in a Pandemic: A Guide for the Dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists date: 2020-06-19 journal: J Am Acad Dermatol DOI: 10.1016/j.jaad.2020.06.051 sha: fab54fa79f7ed29edac3e6a062bbe20ac6ad1b14 doc_id: 832836 cord_uid: 0d2j9zj7 Abstract: Dermatologists treating immune-mediated skin disease must now contend with the uncertainties associated with immunosuppressive use in the context of the SARS-CoV-2 pandemic. Though the risk of infection with many commonly used immunosuppressive agents remains low, direct data evaluating the safety of such agents in COVID-19 are scarce. This article reviews and offers guidance based upon currently available safety data, and the most recent COVID-19 outcome data, in patients with immune-mediated dermatologic disease. The interdisciplinary panel of experts emphasize a stepwise, shared decision-making approach in the management of immunosuppressive therapy. The goal of this article is to help providers minimize the risk of disease flares while simultaneously minimizing the risk of iatrogenic harm during an evolving pandemic. Corresponding author: 24 Omid Zahedi Niaki 25 41 Avenue Louis Pasteur, 319 26 Boston, MA 02115 27 Email: OmidZahediMD@gmail.com 28 29 Funding sources: None 30 31 Disclosures: OZN has participated in an advisory board for Eli Lilly. MA is currently serving as consultant for 32 Boehringer-Ingelheim, NovoCure, and Onquality. He is also currently serving as an investigator for 33 Biogen, Lutris, AnaptyxBio, Boehringer-Ingelheim, OnQuality, Norvartis, ChemoCentryx, UCB Biopharma, 34 and XBiotech. STC has no relevant financial interests to report. LPF has no relevant financial interests to report. JH has no relevant financial interests to report. RGM has no relevant financial interests to report. VEN has no 36 relevant financial interests to report. HBP has no relevant financial interests to report. MMS has been a principle References: 74 2 Tables: 4 3 Supplementary tables: 0 4 Figures: 0 5 Supplementary figures: 0 6 7 Keywords: COVID-19, SARS-CoV-2, immunosuppression, immunosuppressive therapy, 8 autoimmune disease, medical dermatology, dermatology-rheumatology 9 In the context of the current Coronavirus disease 2019 (COVID-19) pandemic, physicians 1 treating patients with immune-mediated dermatologic diseases are tasked with challenging 2 decisions when initiating immunosuppressive therapy or altering the existing regimens of their 3 patients. This article will examine relevant systemic drug safety data obtained from clinical trials, 4 registries, and cohort studies across disciplines to provide expert-derived guidance in the face 5 of much uncertainty. 6 7 Baseline risk in immune-mediated dermatologic disorders: 8 Evaluating the baseline infection risk of patients is an important aspect of risk stratification. 9 Several immune-mediated conditions (such as psoriasis and lupus) are associated with 10 increased infection risk irrespective of exposure to immunomodulatory agents. 1,2 Many of 11 these conditions are further associated with co-morbidities known to predict poor outcomes in 12 COVID-19 infection (e.g., diabetes and obesity in psoriasis patients, asthma in atopic dermatitis 13 patients, interstitial lung disease with connective tissue disorders). 3 Each patient presents a 14 unique set of variables that dictates the approach to their therapy plan. A summary of these 15 considerations is found in table 1. 16 17 Learning from the past: 18 COVID-19 appears to follow a disease course similar to previous highly pathogenic coronavirus 19 infections ( The risk was 1 dose-dependent and minimal with daily doses <10 mg. 11,12 Similarly, observational data from 2 the large CORRONA registry also found increased overall infection risk with prednisone >10 3 mg/day in patients with rheumatoid arthritis (incidence rate ratio, 1.30; 95% CI 1.1-1.5). 13 4 5 Therapeutic potential in COVID-19: 6 Data evaluating the use of systemic corticosteroids in COVID-19 are limited to a small single 7 center retrospective study of 201 patients with SARS-CoV-2 pneumonia. 14 Overall, steroids 8 were associated with worse outcomes, though lower mortality was noted in a subgroup of 84 9 patients with ARDS. Data from the SARS and MERS epidemics are conflicting and many studies 10 have revealed no mortality benefit, delayed viral clearance, and evidence for harm. 15 Conclusions: 7 The current data show no significant risk of infection or infectious complications when 8 antimalarials are used for the treatment of immune-mediated disease and therefore suggest 9 low potential for harm in COVID-19 infection. However, data supporting the use of antimalarials 10 for prevention or treatment of COVID-19 are lacking at present, and such use outside of a 11 hospital or clinical trial is cautioned against. 31 12 13 Oral Small Molecules (azathioprine, mycophenolate mofetil, and cyclosporine) 14 Using The bulk of the safety data regarding JAK inhibitors come from the use of tofacitinib in 2 rheumatoid arthritis. Analysis of the most recent tofacitinib data from RCTs and long-term 3 extension studies in RA reveals serious infection rates of 2.4 per 100 patient years, 42 4 comparable to the event rates reported for biologic DMARDs 43,44 and baricitinib. 45 A particular 5 concern with JAK inhibition is the risk of VZV reactivation and antiviral immunity. This appears 6 to be a class effect due to impairment of the interferon antiviral response. It has been noted 7 across all indications and occurs at an increased rate with both selective and non-selective JAK 8 inhibitors. 46,47,48 9 10 Therapeutic potential in COVID-19: 11 Ruxolitinib (NCT04362137) and baricitinib (NCT04280705) are currently being evaluated in 12 phase III clinical trials for potential therapeutic effect in critically ill COVID-19 patients. It is 13 suggested that preferential inhibition of JAK1 and JAK2 significantly downregulates the 14 production of IL-6 and IFN-y, both of which are implicated in the hyperinflammatory state seen 15 in critically ill COVID-19 patients. 10, 49 Moreover, unlike tofacitinib, baricitinib and ruxolitinib 16 have demonstrated antiviral activity via inhibition of receptor mediated endocytosis of SARS-17 CoV-2 viral particles. 50 18 19 Additional concerns in COVID-19: 20 A high rate of venous thromboembolism (VTE) has been noted in COVID-19, occurring in up to 21 one third of critically ill patients, despite prophylactic anticoagulation. 51,52 As JAK inhibitors 22 carry a 'black box warning' of increased VTE risk, there is reasonable concern that their use may 23 increase the likelihood or severity of VTE when used in patients with COVID-19. 53 24 25 Conclusions: 26 The use of JAK inhibitors is associated with an increased risk of serious infection, herpes zoster 27 reactivation, and VTE. However, recent studies show potential direct antiviral and anti-28 inflammatory effects in COVID-19, seemingly unique to ruxolitinib and baricitinib. Taken The majority of patients on systemic immunosuppressive or immunomodulatory therapy 1 included in these studies did not require hospitalization, and mortality remained a rare 2 outcome. However, systemic corticosteroid use in this patient population appeared to increase 3 the risk of poor outcomes in COVID-19. 4 5 Discussion and recommendations: 6 We believe a patient-centered approach, with shared decision making informed by the data 7 presented herein, will help mitigate risk to our patients. Factors to consider are summarized in 8 Table 1 . Our interpretation of the literature based on the highest quality of evidence available 9 to date is found in Table 4 . The over-arching principles are that immunosuppressive and 10 immunomodulatory therapy can be safely initiated or continued in most patients with the 11 exception of high dose corticosteroid regimens for which caution should be applied. Physicians 12 should alter and optimize regimens in favor of lower risk options where possible, and as 13 outlined more specifically in Tables 3 and 4 . 14 15 Further data regarding the safety of these agents are needed and constitute a key unmet need 16 for our patients. We suggest continuing immunosuppressive/immunomodulatory therapy at the lowest necessary effective dose, as immunosuppression alone does not appear to predict poor COVID-19 outcomes. We do note the following exceptions: a. Chronic systemic steroids should be tapered to daily doses <10 mg prednisone equivalent, if safe to do so. b. Patients on recurrent rituximab dosing may benefit from immunoglobulin level testing. If hypogammaglobulinemia exists, consider altered/delayed dose and/or initiating immunoglobulin therapy. We suggest the following: a. Based on disease severity and baseline risk, consider favoring low-risk/immunomodulatory agents (e.g., apremilast, hydroxychloroquine, methotrexate) over immunosuppressive agents with a higher known or suspected risk of infection (see Table 2 ). b. When medically appropriate, opt for short courses of low-to-moderate doses of systemic corticosteroids over high-dose regimens (e.g., <20 mg prednisone equivalent daily for <2 weeks); if needed for maintenance therapy, consider doses <10 mg daily. c. When possible, avoid starting rituximab, due to its prolonged B-cell depleting effects, if equally efficacious alternative therapies are available; exceptions include mucous membrane blistering disorders. d. If possible, use alternatives to cyclosporine and other agents requiring intensive toxicity/safety monitoring. Although the potential benefit of immunosuppression is being studied in the context of cytokine storm, we suggest that, if possible, immunosuppressive therapy be held in patients testing positive for COVID-19, even if asymptomatic, with the concern being the complication of bacterial infections and pneumonia. Many systemic immunosuppressive drugs have long half-lives, and temporary cessation of therapy is unlikely to result in disease flare. Individual discussions may be considered for severe flares with potentially organ-threatening manifestations. Treatment can resume after recovery (refer to CDC or local health authority for recovery criteria). Exceptions to the above include: 1. Systemic steroids may be tapered but not stopped abruptly. Providers should follow recommendations for corticosteroid stress doses in critically ill patients. 2. Drugs with minimal immunosuppressive potential (e.g., apremilast, antimalarials) may be continued after thorough patient assessment (refer to table 1). Glucocorticoid Therapy and the Risk of Infection in 1 Patients With Newly Diagnosed Autoimmune Disease Association of methotrexate and tumour necrosis 4 factor antagonists with risk of infectious outcomes including opportunistic infections in 5 the CORRONA registry Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients 7 With Coronavirus Disease Effects of early corticosteroid treatment on plasma 10 SARS-associated Coronavirus RNA concentrations in adult patients Systemic Corticosteroid Therapy May Delay Viral Clearance in Patients with Middle 13 East Respiratory Syndrome Coronavirus Infection Corticosteroid Therapy for Critically Ill Patients 16 with Middle East Respiratory Syndrome Corticosteroids as adjunctive 19 therapy in the treatment of influenza Risk of Serious Infection With Biologic and 1 Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and 2 Registry (PSOLAR) Should biologics for psoriasis be interrupted in the 5 era of COVID-19 Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times Dermatol Ther (Heidelb) The risk of respiratory tract infections and 12 symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-13 estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic Rituximab-related viral infections in lymphoma 16 patients Efficacy and safety of different doses and retreatment 18 of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve 19 with active rheumatoid arthritis and an inadequate response to methotrexate (Study 20 Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)) Efficacy and Safety of Retreatment in Patients with 23 Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor 24 Inhibitors: Results from the SUNRISE Trial Longterm Safety of 27 Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Long-Term Safety of Rituximab in Patients With 30 Rheumatoid Arthritis: Results of a Five-Year Observational Study First-line rituximab combined with short-33 term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a 34 prospective, multicentre, parallel-group, open-label randomised trial. The Lancet Repeated courses of rituximab for autoimmune 1 cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement 2 intravenous immunoglobulin Hypogammaglobulinaemia after rituximab 8 treatment--incidence and outcomes Humoral responses after influenza vaccination are 11 severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis 12 Rheum The Effect of Rituximab on Vaccine Responses in Patients 14 with Immune Thrombocytopenia Infections in Dupilumab Clinical Trials in Atopic 17 Dermatitis: A Comprehensive Pooled Analysis Covid-19 in Immune-Mediated Inflammatory Diseases 20 -Case Series from New York Rheumatic disease and COVID-19: initial data 23 from the COVID-19 Global Rheumatology Alliance provider registries but not TNF Antagonists, are 26 Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel 27 Diseases: Results from an International Registry Biologics increase the risk of SARS-CoV-2 30 infection and hospitalization, but not ICU admission and death: Real-life data from a large 31 cohort during red-zone declaration The patient's underlying risk factors (e.g. comorbidities) Contextual factors impacting patient risk (e.g., high-risk occupation, caregiver roles, atrisk individuals in the home or work environment The patient's preferences and level of risk tolerance The level of exposure to healthcare settings dictated by the need for monitoring labs and PsA -19 (17) SLE -19 (17) Other -17 (15) ‡ . When possible, maximize/optimize non-immunosuppressive therapy such as topical steroids High-dose systemic corticosteroids should be avoided where possible, and taper plans should be kept to the minimum necessary dose and duration Notably, our guidance statements are based on expert opinion and interpretation of safety data deemed most relevant, rather than formal guidelines derived from high-quality comparative studies. Limitations include the heterogeneity of the safety data encompassing various autoimmune conditions and the limited reports available on the status of immunosuppressed patients affected by COVID-19. The applicability of the information and recommendations provided herein are limited by the rapidly evolving nature of the COVID-19 pandemic, in addition to patient-specific and local healthcare constraints. Decisions should ultimately be individualized to a specific scenario • This article adds to the limited literature on COVID-19 and immunosuppression. It provides expert opinion based on existing drug safety data and recent COVID-19 outcome data in patients with immune-mediated dermatologic disorders. • The goal is to facilitate management of immunosuppressive drugs and minimize potential for harm in this patient population.